Compare EVF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVF | IFRX |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 81.3M |
| IPO Year | N/A | 2017 |
| Metric | EVF | IFRX |
|---|---|---|
| Price | $5.31 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 93.3K | ★ 647.2K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 10.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | ★ $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | $6.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.20 | $0.71 |
| 52 Week High | $6.84 | $2.77 |
| Indicator | EVF | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 45.22 |
| Support Level | $5.25 | $1.00 |
| Resistance Level | $5.38 | $1.10 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 36.60 | 15.22 |
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.